Insider Cluster (2 insiders) ·Filed Apr 15, 2026

CYTK

CYTOKINETICS INC
BEARISH
Impact 7/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $982K total
Actionable Insight ▼ Bearish

Traders should watch for potential downward pressure on the stock; coordinated C-suite selling at high magnitude relative to typical patterns may indicate private concerns about valuation or upcoming catalysts. Monitor for further filings or news that could clarify intent.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
CYTK ▲ +29.83% at T+60d
SHORT call ✗ call lost -29.83% · α vs SPY -21.69% · entry $65.37 → $84.87
Entry anchored
Apr 14, 03:59 PM ET
via exchange tick
T+1d
+0.08%
call -0.08% · α +0.18%
$65.42
settled 6mo ago
T+5d
+1.35%
call -1.35% · α +0.29%
$66.25
settled 5mo ago
T+20d
+14.44%
call -14.44% · α -8.40%
$74.81
settled 5mo ago
T+60d
+29.83%
call -29.83% · α -21.69%
$84.87
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Two top executives at Cytokinetics, including the CEO and Chief Commercial Officer, sold nearly $1 million in shares over a single day, with both transactions occurring at market prices. This coordinated open-market selling by C-suite leaders signals potential lack of confidence in near-term prospects despite no disclosed negative news.

Key Financial Metrics

Direction
selling
Total Value
$982.1K
Insiders
2

Key Facts

  • CEO Robert Blum sold 7,500 shares for $490,350 at $65.38 per share on April 15, 2026
  • EVP Andrew Callos sold 7,449 shares for $491,782.98 at $66.02 per share on April 15, 2026
  • Total insider selling in the cluster: $982,132.98 over a 7-day window
  • Both transactions were open-market sales (code S), not tax-related or automatic disposals

Financial Impact

$982,133 in open-market share sales by two C-suite executives

insider ownershipinvestor sentiment

Risk Factors

  • Perception of insider pessimism could erode investor confidence
  • Potential for follow-on selling if other insiders act similarly

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CYTK-1776288585732
32 reports for CYTK
Performance horizon
100% Hit rate 8 of 8 directional calls best @ T+20▲ +10.38%Mar 31, 2026
Filters
Rows
Reports for CYTK — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
BEARISH ★ 5/10
$69.31 $67.59▲ +2.48%▲ +4.59%$65.60 (+5.35%)
Sep 11, 2026
20d ago
Insider Cluster
NEUTRAL ★ 2/10
$72.45 $67.56▼ −6.75%▼ −6.86%$65.60 (−9.45%)
Sep 1, 2026
4w ago
Insider Cluster
NEUTRAL ★ 2/10
$71.40 $74.11▲ +3.80%▲ +3.71%$65.60 (−8.12%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$71.40 $74.11▲ +3.80%▲ +3.71%$65.60 (−8.12%)
Aug 29, 2026
4w ago
Press Release
BULLISH ★ 7/10
$70.91 $75.35▲ +6.26%▲ +6.40%$65.60 (−7.49%)
Aug 28, 2026
5w ago
8-K
BULLISH ★ 7/10
$72.09 $72.72▲ +0.87%▲ +0.76%$65.60 (−9.00%)
Jul 30, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$80.42 $81.37▲ +1.18%▼ −2.44%$65.60 (−18.43%)
Jul 27, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$80.62 $77.13▼ −4.33%▼ −5.40%$65.60 (−18.63%)
Jul 23, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$80.74 $80.42▼ −0.40%▼ −0.77%$65.60 (−18.75%)
Jul 14, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$81.93 $79.11▼ −3.44%▼ −2.15%$65.60 (−19.93%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 15, 2026